NCT05539196

Brief Summary

This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
39mo left

Started Jan 2023

Longer than P75 for all trials

Geographic Reach
2 countries

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress50%
Jan 2023Jul 2029

First Submitted

Initial submission to the registry

September 12, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 14, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

January 23, 2023

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2029

Last Updated

March 20, 2026

Status Verified

March 1, 2026

Enrollment Period

6.5 years

First QC Date

September 12, 2022

Last Update Submit

March 18, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Responder Analysis

    Primary Effectiveness will be evaluated through a Responder analysis. Responder is defined as the patient reaching a minimally clinically significant difference on: 1) UDysRS Objective Assessment ON Meds, without clinically significant worsening of MDS-UPDRS Part III OFF Meds aggregated extremity score for treated side Or 2) MDS-UPDRS Part III OFF Meds Motor Exam on the treated side, without clinically significant worsening of UDysRS Objective Assessment ON meds

    5 years

Other Outcomes (1)

  • Safety Analysis

    5 years

Study Arms (1)

Post Exablate Neuro Pallidotomy for Parkinson's Disease with Motor Complications

The population enrolled in this registry will be comprised of male and female patients that plan to be treated using the Exablate Neuro system for advanced, idiopathic Parkinson's disease with medication-refractory moderate to severe motor complications. No intervention is performed under this registry protocol.

Device: Exablate Pallidotomy, Unilateral

Interventions

Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.

Post Exablate Neuro Pallidotomy for Parkinson's Disease with Motor Complications

Eligibility Criteria

Age30 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The population enrolled in this registry will be comprised of male and female patients that plan to be treated using the Exablate Neuro system for advanced, idiopathic Parkinson's disease with medication-refractory moderate to severe motor complications. Subjects must meet the specific eligibility criteria in order to enroll in this Registry.

You may qualify if:

  • Men and women, age 30 years and older.
  • Subject undergoing a planned an Exablate procedure for their Parkinson's Disease with Motor Complications per local institution standard of care.
  • Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all Registry visits.
  • Subject has signed and received a copy of the approved informed consent form.

You may not qualify if:

  • Subject does not agree to participate or is unlikely to participate for the entirety of the Registry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

University of Maryland, Baltimore

Baltimore, Maryland, 21201, United States

RECRUITING

Weill Cornell Medicine

New York, New York, 10065, United States

RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, 19106, United States

RECRUITING

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

RECRUITING

Ohnishi Neurological Center

Akashi, Hyōgo, 674-0064, Japan

RECRUITING

MeSH Terms

Conditions

Movement DisordersParkinson Disease

Condition Hierarchy (Ancestors)

Central Nervous System DiseasesNervous System DiseasesParkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2022

First Posted

September 14, 2022

Study Start

January 23, 2023

Primary Completion (Estimated)

July 31, 2029

Study Completion (Estimated)

July 31, 2029

Last Updated

March 20, 2026

Record last verified: 2026-03

Locations